Join Elicio Therapeutics for a virtual key opinion leader (KOL) event featuring expert oncologists Eileen M. O’Reilly, MD, FASCO (Memorial Sloan Kettering Cancer Center) and Kevin C. Soares, MD (Memorial Sloan Kettering Cancer Center), who will join company management to discuss:

• The unmet need and current treatment landscape for metastatic pancreatic ductal adenocarcinoma (PDAC)
• Camupepimut (ELI-002 7P), Elicio’s investigational AMP-powered immunotherapy targeting common KRAS mutations
• Key Phase 2 findings informing camupepimut’s development strategy
• Opportunities to expand camupepimut into neoadjuvant PDAC, including the design and progress of the ongoing MSK-led, Lustgarten-funded Phase 1 trial

A live question and answer session will follow the formal presentations.